|
| 37939124 | Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. | Clin Cancer Res | 2024 |
| 37097611 | Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer. | Clin Cancer Res | 2023 |
| 36307055 | Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. | Ann Oncol | 2023 |
| 36245263 | Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriers. | J Genet Couns | 2023 |
| 36089892 | Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood. | Clin Genet | 2023 |
| 36346689 | NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects. | Clin Cancer Res | 2023 |
| 36394867 | Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. | JAMA Oncology | 2023 |
| 37856201 | NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. | J Natl Compr Canc Netw | 2023 |
| 37932730 | Protocol to evaluate sequential electronic health record-based strategies to increase genetic testing for breast and ovarian cancer risk across diverse patient populations in gynecology practices. | Implement Sci | 2023 |
| 38010655 | Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival. | | 2023 |
| 37639653 | Development of an Electronic Health Record-Based Clinical Decision Support Tool for Patients With Lynch Syndrome. | JCO Clin Cancer Inform | 2023 |
| 37611220 | Uptake of Genetic Research Results and Patient-Reported Outcomes With Return of Results Incorporating Web-Based Predisclosure Education. | J Clin Oncol | 2023 |
| 36974724 | Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. | J Urol | 2023 |
| 37410931 | WHAM - A prospective study of weight and body composition after risk-reducing bilateral salpingo-oophorectomy. | | 2023 |
| 36971103 | Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. | | 2023 |
| 37146473 | Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. | Lung Cancer | 2023 |
| 36893711 | OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. | | 2023 |
| 37015340 | Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer. | J Natl Compr Canc Netw | 2023 |
| 37132126 | Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations. | BJOG | 2023 |
| 36482193 | Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. | Br J Cancer | 2023 |
| 36748334 | Measuring high-risk parents' opinions about direct-to-consumer genetic testing for adult-onset inherited cancer syndromes in their adolescent and young adult children. | J Genet Couns | 2023 |
| 37253112 | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C. | Cancer Res | 2023 |
| 36623243 | Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>. | J Clin Oncol | 2023 |
| 37535879 | Biallelic <i>BRCA</i> Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline <i>BRCA1/2</i> Carriers. | JCO Precis Oncol | 2023 |
| 37486343 | The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib. | Clin Cancer Res | 2023 |
| 37291133 | Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles. | Nat Commun | 2023 |
| 35242827 | <i>BRCA1/2</i> Mutations and Cardiovascular Function in Breast Cancer Survivors. | Front Cardiovasc Med | 2022 |
| 36369506 | Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer. | npj Breast Cancer | 2022 |
| 36107166 | Impact of integrating genomic data into the electronic health record on genetics care delivery. | Genet Med | 2022 |
| 35700704 | Cancer vaccines. | Cancer Cell | 2022 |
| 36228963 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. | Ann Oncol | 2022 |
| 36344544 | Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers. | Nat Commun | 2022 |
| 35810751 | Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. | Lancet Oncology, The | 2022 |
| 35554533 | Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. | Hum Mol Genet | 2022 |
| 36205748 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 35736817 | Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay. | Clin Cancer Res | 2022 |
| 36331239 | Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition. | JCO Precis Oncol | 2022 |
| 36051752 | Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations. | Genes and Cancer | 2022 |
| 35778289 | The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point. | Pathology | 2022 |
| 34173196 | Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. | J Gen Intern Med | 2022 |
| 34906490 | Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. | Genet Med | 2022 |
| 34906479 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 35201851 | <i>PTEN</i> Loss and <i>BRCA1</i> Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer. | JCO Precis Oncol | 2022 |
| 34890045 | A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). | Cancer | 2022 |
| 34711450 | Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. | Eur Urol | 2022 |
| 34500047 | Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. | Ann Oncol | 2021 |
| 33972087 | What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. | Gynecologic Oncology | 2021 |
| 33970687 | Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>. | J Clin Oncol | 2021 |
| 34292776 | Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. | J Clin Oncol | 2021 |
| 34283078 | Blood Arsenic Levels as a Marker of Breast Cancer Risk among <i>BRCA1</i> Carriers. | Cancers (Basel) | 2021 |